MAUNA KEA TECHNOLOGIES (MKEA.PA) Stock Price & Overview
EPA:MKEA • FR0010609263
Current stock price
The current stock price of MKEA.PA is 0.62 EUR. Today MKEA.PA is down by 0%. In the past month the price decreased by -3.43%. In the past year, price decreased by -29.47%.
MKEA.PA Key Statistics
- Market Cap
- 28.738M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
MKEA.PA Stock Performance
MKEA.PA Stock Chart
MKEA.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MKEA.PA. When comparing the yearly performance of all stocks, MKEA.PA is a bad performer in the overall market: 84.84% of all stocks are doing better.
MKEA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MKEA.PA. Both the profitability and financial health of MKEA.PA have multiple concerns.
MKEA.PA Earnings
MKEA.PA Forecast & Estimates
8 analysts have analysed MKEA.PA and the average price target is 1.99 EUR. This implies a price increase of 220.81% is expected in the next year compared to the current price of 0.62.
For the next year, analysts expect an EPS growth of -62.13% and a revenue growth -18.48% for MKEA.PA
MKEA.PA Groups
Sector & Classification
MKEA.PA Financial Highlights
Over the last trailing twelve months MKEA.PA reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 28.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MKEA.PA Ownership
MKEA.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1MDT | MEDTRONIC PLC | 14.12 | 96.021B | ||
| 2M6 | MEDTRONIC PLC | 14.16 | 94.468B | ||
| SHL | SIEMENS HEALTHINEERS AG | 14.69 | 43.891B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 16.72 | 24.41B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 16.67 | 24.333B | ||
| BIM | BIOMERIEUX | 18.93 | 10.8B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 19.67 | 3.782B | ||
| DIA | DIASORIN SPA | 15.63 | 3.541B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 14.87 | 2.49B | ||
| DRW3 | DRAEGERWERK AG - PREF | 12.1 | 1.844B | ||
| DRW8 | DRAEGERWERK AG | 9.52 | 1.452B | ||
| ELN | EL.EN. SPA | 18.17 | 1.104B | ||
| EUZ | ECKERT & ZIEGLER SE | 19.36 | 990.277M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About MKEA.PA
Company Profile
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France and currently employs 56 full-time employees. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.
Company Info
IPO: 2011-07-05
MAUNA KEA TECHNOLOGIES
9, rue d'Enghien
Paris ILE-DE-FRANCE FR
Employees: 56
Phone: 33148240345.0
MAUNA KEA TECHNOLOGIES / MKEA.PA FAQ
Can you describe the business of MAUNA KEA TECHNOLOGIES?
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France and currently employs 56 full-time employees. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.
What is the current price of MKEA stock?
The current stock price of MKEA.PA is 0.62 EUR.
Does MKEA stock pay dividends?
MKEA.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MKEA stock?
MKEA.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists MKEA stock?
MKEA.PA stock is listed on the Euronext Paris exchange.
Is MAUNA KEA TECHNOLOGIES (MKEA.PA) expected to grow?
The Revenue of MAUNA KEA TECHNOLOGIES (MKEA.PA) is expected to decline by -18.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.